Browse the evidence

In patients with type 2 diabetes and high cardiovascular risk (CAC ≥ 100), intensified multifactorial treatment using SGLT2 inhibitors and GLP-1 receptor agonists combined with high-intensity lipid-lowering therapy reduces cardiovascular events compared to standard treatment.

If you have Type 2 Diabetes and a high Coronary Artery Calcification (CAC) score (≥100), current standard care may not be enough. This trial tests whether adding specific heart-protective diabetes medications (SGLT2 inhibitors and GLP-1 agonists) along with aggressive cholesterol and blood pressure management significantly reduces your risk of heart attack, stroke, or heart failure compared to standard care. You should discuss your CAC score and whether intensified therapy is appropriate for your specific risk profile with your doctor.

In patients with Type 2 Diabetes and a CAC score of 0 (very low risk), de-escalating multifactorial treatment targets (e.g., less intensive lipid and blood pressure management) is non-inferior to standard treatment regarding cardiovascular events.

If you have Type 2 Diabetes but a Coronary Artery Calcification (CAC) score of 0, your risk of a cardiovascular event is very low (about 1% over 5 years). This trial investigates whether it is safe to reduce the intensity of your cholesterol and blood pressure medications compared to standard care. If your CAC is 0, you might be able to simplify your medication regimen with your doctor, focusing on glucose control and avoiding side effects, without significantly increasing your heart risk.

Semaglutide effectively reverses alectinib-induced excessive weight gain in ALK+ NSCLC patients, though discontinuation due to gallstone pancreatitis can lead to weight regain.

If you are on alectinib and gaining significant weight, semaglutide can help you lose it, but you must get a baseline gallbladder ultrasound first. If you develop abdominal pain, stop the drug immediately as it may cause pancreatitis, which will cause you to regain the weight you lost.

Coadministration of SGLT2 inhibitors and tirzepatide creates a synergistic risk for euglycemic ketoacidosis (EKA), a life-threatening condition characterized by ketone production and acidosis despite normal blood glucose levels.

If you are taking both an SGLT2 inhibitor (like empagliflozin) and tirzepatide, be aware that you are at risk for a rare but serious condition called euglycemic ketoacidosis (EKA). Unlike typical diabetic ketoacidosis, your blood sugar may remain normal, so do not rely on glucose readings alone. If you experience persistent nausea, vomiting, or extreme fatigue, seek medical attention immediately and ask for ketone testing, even if your blood sugar is not high.

Observational studies claiming GLP-1 receptor agonists reduce cancer risk are currently methodologically flawed and cannot support clinical policy due to high risk of bias.

Do not rely on current observational studies to claim that GLP-1 drugs prevent cancer. The existing data is methodologically flawed and cannot yet inform clinical practice or public health policy.

The presence of the rare BDNF p.Thr2Ile variant is associated with a suboptimal response to high-dose tirzepatide treatment, resulting in significantly less weight loss compared to clinical trial averages.

If you have the rare BDNF p.Thr2Ile variant, you might experience less weight loss from tirzepatide than the average patient. Discuss your genetic profile with your doctor to manage expectations and explore alternative treatments.